TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11454733

Group type: EXPERIMENTAL
Intervention: Single oral dose of [(14)C]linezolid 500 mg (100-microCi)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10-day regimen of unlabeled linezolid 500 mg b.i.d.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Single radioactive dose of linezolid
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PNU-142586 (T(max) of 3-5 h)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PNU-142300 (T(max) of 2-3 h)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Linezolid and PNU-142586 exposures at steady-state
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Overall disposition of linezolid
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Formation of PNU-142586
Number of subjects: 15
Study: 9279247

Group type: EXPERIMENTAL
Intervention: RV16 (n = 19)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Diluent (Control, n = 8)
Number of subjects: 27
Study: 7525901

Group type: EXPERIMENTAL
Intervention: Intra-arterial injection of 131I-iodized oil (Treated group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Medical support (Control group)
Number of subjects: 27
Study: 3596907

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 31

Group type: COMPARATOR
Intervention: No tranexamic acid (control)
Number of subjects: 31
Study: 30014184

Group type: EXPERIMENTAL
Intervention: EG-1962 (600 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral nimodipine (active control)
Number of subjects: 0
Study: 26969198

Group type: EXPERIMENTAL
Intervention: Immediate delivery
Number of subjects: 703

Group type: COMPARATOR
Intervention: Expectant monitoring
Number of subjects: 703
Study: 25556905

Group type: EXPERIMENTAL
Intervention: Increased vertical overlap group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 23980674

Group type: EXPERIMENTAL
Intervention: Tasquinimod
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study: 20830660

Group type: EXPERIMENTAL
Intervention: Family-oriented inpatient rehabilitation program
Number of subjects: 302

Group type: COMPARATOR
Intervention: Healthy control group from the National Health Interview and Examination Survey for Children and Adolescents
Number of subjects: 302
Study: 19119088

Group type: EXPERIMENTAL
Intervention: Total Thyroidectomy (TT)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Near Total Thyroidectomy (NTT)
Number of subjects: 143
Study: 16757502

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated dressing
Number of subjects: 8
Study: 15587331

Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition (EEN)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Total parenteral hyperalimentation (TPN)
Number of subjects: 42
Study: 11041466

Group type: EXPERIMENTAL
Intervention: Percutaneous fibrin sheath stripping (PFSS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Over-the-wire catheter exchange (EX)
Number of subjects: 30
Study: 9300476

Group type: EXPERIMENTAL
Intervention: Normothermic perfusion (36 degrees C)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hypothermic perfusion (28 degrees C)
Number of subjects: 50
Study: 8101150

Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1 mg ondansetron
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.25 mg ondansetron
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.1 mg ondansetron
Number of subjects: 50
Study: 2873161

Group type: EXPERIMENTAL
Intervention: Terfenadine suspension (30 mg twice daily for children <30 kg; 60 mg twice daily for children >30 kg)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Terfenadine suspension
Number of subjects: 119
Study: 3348158

Group type: EXPERIMENTAL
Intervention: Vitamin E intake
Number of subjects: 0
Study: 30656507

Group type: COMPARATOR
Intervention: Model 1 (usual clinical variables)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Model 2 (lung and systemic inflammatory biomarkers)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Model 3 (combination of Models 1 and 2)
Number of subjects: 173
Study: 29099102

Group type: EXPERIMENTAL
Intervention: Melatonin (MEL) at doses of 25 mg orally every 12 hours for 12 months
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo with corn starch
Number of subjects: 13
Study: 26050073

Group type: EXPERIMENTAL
Intervention: Feedback-controlled robotics-assisted treadmill exercise (FC-RATE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional robotics-assisted treadmill exercise (RATE)
Number of subjects: 20
Study: 23537970

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 1721

Group type: COMPARATOR
Intervention: Abciximab plus heparin
Number of subjects: 1721
Study: 21813109

Group type: EXPERIMENTAL
Intervention: Colesevelam (3.75 g/day)
Number of subjects: 20
Study: 19785815

Group type: EXPERIMENTAL
Intervention: Metformin as a monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glibenclamide as a monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin treatment
Number of subjects: 0
Study: 16716847

Group type: EXPERIMENTAL
Intervention: Twelve Steps (TS) treatment
Number of subjects: 453
Study: 15525622

Group type: EXPERIMENTAL
Intervention: Gargling with povidone-iodine (2.5 mg/mL, 25 mL)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (gargling with tap water, 25 mL)
Number of subjects: 38
Study: 11561930

Group type: EXPERIMENTAL
Intervention: Nortriptyline plus perphenazine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nortriptyline plus placebo
Number of subjects: 36
Study: 9428831

Group type: EXPERIMENTAL
Intervention: Acarbose (3 x 100 mg/day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Metformin (2 x 850 mg/day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 8296490

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol and levonorgestrel
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol and desogestrel
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control cycle (no treatment)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 3-month washout period
Number of subjects: 14
Study: 3329123

Group type: EXPERIMENTAL
Intervention: Glucose meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fructose meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lactose meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Milk meal
Number of subjects: 10
Study: 30150504

Group type: EXPERIMENTAL
Intervention: One-stage full-mouth oral disinfection (FMD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Quadrant scaling and root planing (Q-SRP)
Number of subjects: 40
Study: 26455907

Group type: EXPERIMENTAL
Intervention: r-tPA + resveratrol
Number of subjects: 0

Group type: COMPARATOR
Intervention: r-tPA + placebo
Number of subjects: 0
Study: 24833047

Group type: EXPERIMENTAL
Intervention: LARC script
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control (no LARC script)
Number of subjects: 800
Study: 22057852

Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg twice weekly (fasting)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg twice weekly (high-fat breakfast)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg twice weekly (normal breakfast)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Panobinostat (overall treatment)
Number of subjects: 36
Study: 19953620

Group type: EXPERIMENTAL
Intervention: Blowing time ratio
Number of subjects: 0
Study: 17234565

Group type: EXPERIMENTAL
Intervention: Intended readings by mediums
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control readings
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mediums' reading choices
Number of subjects: 8
Study: 15924807

Group type: EXPERIMENTAL
Intervention: indapamide + fosinopril (I + F, n = 151)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: atenolol + nitrendipine (A + N, n = 160)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: atenolol + nitrendipine + metformin (A + N + M, n = 152)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Comparison of I + F vs A + N
Number of subjects: 463

Group type: COMPARATOR
Intervention: Comparison of A + N vs A + N + M
Number of subjects: 463
Study: 11898874

Group type: EXPERIMENTAL
Intervention: Finger blanching (frequent attacks, affecting nine or ten digits)
Number of subjects: 12907

Group type: EXPERIMENTAL
Intervention: Finger blanching (50 or more attacks in the past year)
Number of subjects: 12907

Group type: EXPERIMENTAL
Intervention: Finger blanching (nine to ten digits affected)
Number of subjects: 12907
Study: 10193541

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EN) started not later than 6 h after admission (group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Delayed enteral nutrition (EN) started later than 24 h after admission (group B)
Number of subjects: 28
Study: 7572772

Group type: EXPERIMENTAL
Intervention: Acupuncture at Tsu San Li (St-36)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-acupuncture point
Number of subjects: 0
Study: 2299213

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccines with increasing antigen concentrations
Number of subjects: 140
Study: 7027780

Group type: EXPERIMENTAL
Intervention: High nutrition supplement (800 kcal and 40 g of protein/day)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Low nutrition supplement (80 kcal/day)
Number of subjects: 294
Study: 31017305

Group type: EXPERIMENTAL
Intervention: Audit and feedback intervention aimed at primary care centers, involving structured quality reports on medication use and diagnosis recording, sent in 2015.
Number of subjects: 12766

Group type: COMPARATOR
Intervention: Control centers (no specific intervention).
Number of subjects: 12766
Study: 29529508

Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy (DBT) skills training
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Acceptance without judgment (as a dimension of mindfulness)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 84
Study: 26881973

Group type: EXPERIMENTAL
Intervention: Diuretic renogram in volatile substance abusers
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 29
Study: 26357798

Group type: EXPERIMENTAL
Intervention: HES (130/.42)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gelatin
Number of subjects: 40
Study: 22247115

Group type: EXPERIMENTAL
Intervention: Probiotics and organic acids (1 g/L in water) including Lactobacillus acidophilus, Lactobacillus casei, Streptococcus faecium, Saccharomyces cerevisiae, 1% sorbic acid, and 0.2% citric acid for 7 days (T2)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Probiotics and organic acids (1 g/L in water) for 14 days (T3)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no probiotics or organic acids, T1)
Number of subjects: 300
Study: 19243831

Group type: COMPARATOR
Intervention: Phacoemulsification alone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combined phacotrabeculectomy with adjunctive mitomycin C
Number of subjects: 51
Study: 17258092

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 25-microg low-dose (LD) UCN 2
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100-microg high-dose (HD) UCN 2
Number of subjects: 8
Study: 15350324

Group type: EXPERIMENTAL
Intervention: Mechanical pupil dilatation with iris‐retractor hooks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Polymethyl methacrylate (PMMA) pupil dilator‐ring
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Beehler pupil dilator
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bimanual stretching
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mechanical pupil dilatation methods (all groups)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Iris‐retractor hooks and PMMA pupil‐dilator ring
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of added surgical time
Number of subjects: 40
Study: 11429363

Group type: EXPERIMENTAL
Intervention: 1% prilocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5% ropivacaine
Number of subjects: 60
Study: 9842626

Group type: EXPERIMENTAL
Intervention: Behavioural hearing tactics treatment
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 63
Study: 7857367

Group type: EXPERIMENTAL
Intervention: Simvastatin on a high fat diet (40% energy)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Simvastatin on a low fat diet (22% energy)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Simvastatin on a low fat diet
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Simvastatin with dietary fat reduction
Number of subjects: 25
Study: 2678684

Group type: EXPERIMENTAL
Intervention: Antiandrogens monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with antiandrogens and castration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Castration alone
Number of subjects: 0
Study: 1102567

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glucagon (1-mg dose)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 9
Study: 31812918

Group type: EXPERIMENTAL
Intervention: Patient-initiated follow-up (PIFU) supported by a self-management approach
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Self-management approach
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Patient-initiated follow-up (PIFU)
Number of subjects: 17
Study: 30982953

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (DEX) 3.28 μg kg-1
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (DEX)
Number of subjects: 53
Study: 28704880

Group type: EXPERIMENTAL
Intervention: Indoor cycling training at a local gym for 12 weeks, average 2.6 times per week
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sedentary lifestyle
Number of subjects: 42
Study: 25277638

Group type: EXPERIMENTAL
Intervention: Morphine plus remifentanil (MR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine (M)
Number of subjects: 60
Study: 23719683

Group type: EXPERIMENTAL
Intervention: Oral rhPTH(1-31)NH2 tablets (5 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Subcutaneous teriparatide (20 μg daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 32
Study: 21767001

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 130
Study: 19512867

Group type: EXPERIMENTAL
Intervention: Buspirone (60 mg orally)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (intravenous infusion to target plasma concentration of 0.6 ng/ml)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of buspirone and dexmedetomidine
Number of subjects: 8

Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 8
Study: 16679090

Group type: EXPERIMENTAL
Intervention: Atorvastatin (group I)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (group II)
Number of subjects: 48
Study: 15596193

Group type: EXPERIMENTAL
Intervention: Goserelin 10.8 mg every 84 days
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg every 28 days
Number of subjects: 247
Study: 11413430

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amicar
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 9210777

Group type: EXPERIMENTAL
Intervention: Hatha yoga therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Traditional group psychotherapy
Number of subjects: 61
Study: 8682922

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR) using e-PTFE membrane
Number of subjects: 28

Group type: COMPARATOR
Intervention: Flap debridement alone (Control)
Number of subjects: 28
Study: 1978164

Group type: EXPERIMENTAL
Intervention: 200,000 IU vitamin A every six months
Number of subjects: 15775

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15775
Study: 90859

Group type: EXPERIMENTAL
Intervention: Preoperative intravenous metronidazole
Number of subjects: 83

Group type: COMPARATOR
Intervention: Intravenous normal saline (control)
Number of subjects: 83
Study: 31639775

Group type: EXPERIMENTAL
Intervention: Probiotic implantation to the dorsum of the tongue (PB)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tongue scraping (TS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mouthwash alone (MW)
Number of subjects: 100
Study: 28662043

Group type: EXPERIMENTAL
Intervention: Surveillance program plus annual MDA if warranted
Number of subjects: 52

Group type: COMPARATOR
Intervention: Annual MDA alone if warranted
Number of subjects: 52
Study: 27649551

Group type: EXPERIMENTAL
Intervention: Concurrent 50 Gy (in 4 fractions) to liver
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sequential 50 Gy (in 4 fractions) to liver
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Concurrent 50 Gy (in 4 fractions) to lung
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sequential 50 Gy (in 4 fractions) to lung
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sequential 60 Gy (in 10 fractions) to lung or liver
Number of subjects: 35
Study: 23650297

Group type: EXPERIMENTAL
Intervention: Combined intervention (family-focused and clinician-focused)
Number of subjects: 22486

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22486

Group type: EXPERIMENTAL
Intervention: Clinician-focused intervention
Number of subjects: 22486
Study: 21232669

Group type: EXPERIMENTAL
Intervention: Vernakalant (3 mg/kg infusion for 10 min, followed by a 15-min observation, and a second infusion of 2 mg/kg if still in AF)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 254

Group type: COMPARATOR
Intervention: Amiodarone (60-min infusion of 5 mg/kg followed by a maintenance infusion of 50 mg over an additional 60 min)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 254
Study: 19143902

Group type: EXPERIMENTAL
Intervention: Valacyclovir 2 g orally twice daily for 1 day and clobetasol gel 0.05% twice daily for 3 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 17250931

Group type: EXPERIMENTAL
Intervention: Modified vaccinia virus Ankara (MVA) with DNA priming
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Modified vaccinia virus Ankara (MVA) alone
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 192
Study: 15093954

Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg) plus Pindolol (5 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Paroxetine plus Placebo
Number of subjects: 6
Study: 11428178

Group type: EXPERIMENTAL
Intervention: Wild yam cream
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 23
Study: 9679620

Group type: EXPERIMENTAL
Intervention: Enalapril (15 mg once daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Captopril (2-4 times daily)
Number of subjects: 62
Study: 1793422

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group therapy (CBGT) for a period of 3 months
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group therapy (CBGT)
Number of subjects: 91
Study: 6871067

Group type: EXPERIMENTAL
Intervention: Nuelin Depot 350 mg with antacid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Theo-Dur 300 mg with antacid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nuelin Depot 350 mg without antacid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Theo-Dur 300 mg without antacid
Number of subjects: 12
Study: 30775145

Group type: EXPERIMENTAL
Intervention: 2 g of oral cephalexin
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 30111262

Group type: EXPERIMENTAL
Intervention: Percutaneous mastoid electrical stimulator (PMES)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sham stimulation (placebo control)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: PMES
Number of subjects: 140
Study: 26782276

Group type: EXPERIMENTAL
Intervention: Preoperative nutrition program with immune modulating formulae (enriched with arginine, omega-3 fatty acids and nucleotides) for ten days
Number of subjects: 58

Group type: COMPARATOR
Intervention: Normal diet (Control)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Preoperative nutrition program with immune modulating formulae
Number of subjects: 58
Study: 25084967

Group type: EXPERIMENTAL
Intervention: Low glycaemic index dietary intervention
Number of subjects: 542

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Maternal gestational weight gain
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Non-smoking status
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Maternal age, smoking status, maternal pre-pregnancy arm circumference, percentage energy from saturated fat in late pregnancy, postprandial glucose at 28 weeks gestation, trimester 2 glycaemic load
Number of subjects: 542
Study: 22829849

Group type: EXPERIMENTAL
Intervention: Single allogenic mesenchymal stem cells transplantation (MSCT) at a dose of one million MSCs per kilogram of body weight.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Double allogenic mesenchymal stem cells transplantation (MSCT).
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Single MSCT.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Double MSCT.
Number of subjects: 58
Study: 18823912

Group type: EXPERIMENTAL
Intervention: Barcode medication administration (BCMA) system
Number of subjects: 958
Study: 17147514

Group type: EXPERIMENTAL
Intervention: Ischaemic handgrip (IHG) at 40% MVC followed by post-exercise circulatory occlusion (PECO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-ischaemic handgrip (HG) at 40% MVC
Number of subjects: 10
Study: 15939922

Group type: EXPERIMENTAL
Intervention: FOLFIRI (irinotecan 180 mg/m(2) on day 1 with LV 100 mg/m(2) and FU 400 mg/m(2) bolus, FU 600 mg/m(2) infusion)
Number of subjects: 360

Group type: COMPARATOR
Intervention: FOLFOX4 (oxaliplatin 85 mg/m(2) on day 1 with LV5FU2 regimen)
Number of subjects: 360